Patient- and Clinician-Reported Outcomes for Tirbanibulin in Actinic Keratosis in Clinical Practice Across the United States (PROAK)
Journal of Drugs in Dermatology · 2024
DOI: 10.36849/jdd.8264 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Drugs in Dermatology, 2024. Verfasst von Todd Schlesinger und 11 weiteren Autor:innen. Hauptthemen laut MEDLINE: Keratosis, Actinic, Patient Reported Outcome Measures, Patient Satisfaction, Quality of Life. Die Arbeit wurde bisher 12-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Schlesinger, T., Kircik, L., Lebwohl, M., Patel, V. A., Berman, B., Bhatia, N., Rigel, D., Armstrong, A., Rosso, J. D., Narayanan, S., Koscielny, V., & Kasujee, I. (2024). Patient- and Clinician-Reported Outcomes for Tirbanibulin in Actinic Keratosis in Clinical Practice Across the United States (PROAK). Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.8264
Vancouver
Schlesinger T, Kircik L, Lebwohl M, Patel VA, Berman B, Bhatia N, et al. Patient- and Clinician-Reported Outcomes for Tirbanibulin in Actinic Keratosis in Clinical Practice Across the United States (PROAK). Journal of Drugs in Dermatology. 2024. doi:10.36849/jdd.8264
BibTeX
@article{Schlesinger2024,
author = {Schlesinger, Todd and Kircik, Leon and Lebwohl, Mark and Patel, Vishal A and Berman, Brian and Bhatia, Neal and Rigel, Darrell and Armstrong, April and Rosso, James Del and Narayanan, Siva and Koscielny, Volker and Kasujee, Ismail},
title = {Patient- and Clinician-Reported Outcomes for Tirbanibulin in Actinic Keratosis in Clinical Practice Across the United States (PROAK)},
journal = {Journal of Drugs in Dermatology},
year = {2024},
doi = {10.36849/jdd.8264}
}
EUVIMED